FDA Determines Regulatory Review Period for Xience Prime Ll Everolimus Eluting Coronary Stent System

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the Xience Prime Ll Everolimus Eluting Coronary Stent System, a medical device, in accordance with federal regulations, following a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO).